Moderna News - January 2026
Moderna Rallies on Five-Year Cancer Vaccine Data, Pivots Away from Vaccine Development
Moderna and Merck announced positive five-year follow-up data for their personalized mRNA cancer vaccine combined with Keytruda, showing it maintained a 49%...
Moderna Shares Plunge as CEO Halts Funding for New Phase 3 Vaccine Trials
Moderna shares plunged 8.75% to $47.33 after CEO Stéphane Bancel announced the company would not fund new Phase 3 vaccine trials in the foreseeable future,...
Moderna CEO Stephane Bancel Announces Halt to New Late-Stage Vaccine Trial Investment
Moderna announced a major strategic pivot, ceasing investment in new late-stage vaccine trials and instead redirecting capital toward its oncology and heart...
🟢 Moderna is trading 3.3% up in after-hours trading on positive oncology data momentum
MRNA is trading at $51.46 (+3.3%) in after-hours, extending the significant intraday rally (which closed at +15.8%) driven by positive five-year follow-up data...
🟢 Moderna is trading 6% up today after lifting 2025 revenue outlook
MRNA is trading at $41.83 (+6.28%) after raising its 2025 revenue forecast to ~$1.9B and outlining major operating expense cuts. * The company reiterated...